drugset / Trial / NCT03919578

Protectivity and Safety Following Recombinant Hepatitis B Vaccine

NCT03919578

Phase 2/3 Completed 536 enrolled PT Bio Farma
RandomizedParallel-groupQuadruple-blindPrevention

Summary

Protectivity and Safety Following Recombinant Hepatitis B Vaccine with different source of Hepatitis B bulk compared to Hepatitis B (Bio Farma) vaccine in Indonesian Population

Timeline

Start
2019-09-11
Primary completion
2020-01-30
Completion
2020-02-28

Drugs

EvaluationDrugModalityDoseRoute
Comparator Recombinant Hepatitis B (Bio Farma) Vaccine 1 ml
Subject recombinant hepatitis B vaccine Vaccine 1 ml

Indications

No indication recorded.